WO2016073529A1 - Skincare formulations and regimens - Google Patents
Skincare formulations and regimens Download PDFInfo
- Publication number
- WO2016073529A1 WO2016073529A1 PCT/US2015/058897 US2015058897W WO2016073529A1 WO 2016073529 A1 WO2016073529 A1 WO 2016073529A1 US 2015058897 W US2015058897 W US 2015058897W WO 2016073529 A1 WO2016073529 A1 WO 2016073529A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- extract
- skin
- acid
- oil
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/29—Titanium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Definitions
- Skin changes are one of the most prominent signs of aging. Throughout aging, the skin can develop lines and wrinkles, undergo a loss of elasticity, develop spots and pigmentation, redden due to an increase in capillary appearance, lose radiance, roughen, develop an uneven tone, dry, thin, and/or become sallow. Further, acute and chronic inflammation as well as Reactive Oxygen Species (ROS) can lead to skin cell degradation and ultimately cell death, which can contribute to the signs of skin aging. Changes to the skin can begin in the mid to late 20's and can both result in injury or disease and be cosmetically undesirable. Accordingly, a skincare formulation and regimen that can slow the aging of skin and/or help reduce the visible signs of aging is needed.
- ROS Reactive Oxygen Species
- composition comprising: at least one neolignan, ectoin, and a molecule of Formula I:
- R ls R 2 and R 3 are independently H, methyl, ethyl, propyl, or isopropyl; wherein X is S or O.
- the result is a reduction of at least one symptom of skin aging.
- Ri, R 2 and R 3 are methyl.
- the molecule of Formula I is ergothioneine (EGT).
- the at least one neolignan is honokiol or a derivative thereof. Honokiol may be provided in the form of magnolia bark extract.
- compositions described herein comprising about 0.01% w/w-25% w/w neolignan, 0.1% w/w-70%> w/w molecule of Formula I, and 0.1 w/w-25% w/w ectoin based on the total weight of the composition; wherein said molecule of Formula I is:
- R ls R 2 and R 3 are independently H, methyl, ethyl, propyl, or isopropyl; wherein X is S or O.
- X is S.
- R ls R 2 and R 3 are methyl.
- the molecule of Formula I is ergothioneine (EGT).
- composition for cosmetic use comprising: at least one neolignan; at least one neuropeptide; and a molecule of Formula I:
- R ls R 2 and R 3 are independently H, methyl, ethyl, propyl, or isopropyl; wherein X is S or O.
- X is S.
- Ri, R 2 and R 3 are methyl.
- the molecule of Formula I is ergothioneine (EGT).
- the at least one neolignan is honokiol.
- the neuropeptide comprises the sequence: Tyr-D- Ala-Gly-Phe-Leu, or the sequence Glu-Glu-Met-Gln-Arg-Arg.
- composition for cosmetic use comprising sergothioneine; honokiol; ectoin; a first polypeptide comprising the sequence Tyr-D-Ala-Gly-Phe-Leu (pentapeptide-18) or a derivative thereof; a second polypeptide comprising the sequence Ac- Glu-Glu-Met-Gln- Arg-Arg -CONH2 (Acetyl Hexapeptide-8) or a derivative thereof; a third polypeptide comprising a palmitic acid conjugate of a polypeptide comprising the sequence Gly-Gln-Pro-Arg (Palmitoyl Tetrapeptide-7) or a derivative thereof; and a fourth polypeptide comprising the sequence Ac-beta-Ala-His-Ser-His (Acetyl Tetrapeptide-5) or a derivative thereof.
- a formulation to help reduce the visible signs of skin aging includes magnolia bark extract, ergothioneine, and ectoin.
- the formulation can include 15-25% magnolia bark extract, 50-70% ergothioneine, and 15-25% ectoin based on the total weight of the composition.
- the magnolia bark extract can be in liposomal form.
- the formulation can be part of a cream or pad.
- the cream or pad further can further include Vitamin C Ester, Peptide Blends, Alpha Hydroxy and Beta Hydroxy Acids, Hyaluronic Acid, Mushroom Ferment Extract, Multi-mineral Blends (Copper-Magnesium-Zinc), Phospholipids (for instance Lecithin), Caffeine, and/or Micro-Algae Blends.
- composition for cosmetic use comprising: at least one neolignan; at least one ultraviolet spectrum attenuating agent comprising a plurality of nanoparticles or microparticles; and a molecule of Formula I:
- R ls R 2 and R 3 are independently H, methyl, ethyl, propyl, or isopropyl; wherein X is S or O. In some cases, in the molecule of Formula I, X is S. In some cases, R ls R 2 and R 3 are methyl. In some cases, the molecule of Formula I is ergothioneine (EGT).
- the neolignan may be honokiol.
- the at least one ultraviolet spectrum attenuating agent comprises zinc oxide, titanium dioxide, combinations or derivatives thereof.
- the composition may also comprise a plurality of hyaluronic microspheres.
- a method of reducing the visible signs of skin aging includes at least one of: (1) cleansing the skin; (2) exfoliating the skin with an exfoliating formulation; (3) treating the skin with a treatment formulation; and (4) moisturizing the skin with a moisturizing formulation.
- the exfoliating formulation, the treatment formulation, or the moisturizing formulation includes magnolia bark extract, ergothioneine, and ectoin.
- These and other embodiments can include one of at least one of: (1) cleansing the skin; (2) exfoliating the skin with an exfoliating formulation; (3) treating the skin with a treatment formulation; and (4) moisturizing the skin with a moisturizing formulation.
- the method can further include repeating the steps twice daily.
- the method can further include repeating the steps for 30 days.
- Figure 1 is a chart showing ingredients and uses of a skincare composition.
- Figure 2 is a table showing ingredients of a peel pad.
- Figure 3 is a table showing ingredients of a face and eye serum.
- Figure 4 is a table showing ingredients of a moisture injection cream.
- Figure 5 is a table showing ingredients of a moisturizer with SPF 20.
- Figure 6 is a table showing ingredients of a moisturizer with SPF 32.
- Figure 7 is a table showing ingredients of an eye lift product.
- Figure 8 is a flow chart for skin treatment.
- Figure 9 is a table showing ingredients of a composition described herein.
- Figure 10 is a table showing ingredients of a composition described herein.
- Described herein is a topical formulation and method of use for helping to reduce visible signs of aging in a population.
- composition comprising: at least one neolignan, ectoin, and a molecule of Formula I:
- R ls R 2 and R 3 are independently H, methyl, ethyl, propyl, or isopropyl; wherein X is S or O.
- X is S or O.
- the contacting results in a reduction of at least one symptom of skin aging.
- X is S.
- Ri, R 2 and R 3 are methyl.
- the molecule of Formula I is ergothioneine (EGT).
- the at least one neolignan is honokiol or a derivative thereof. Honokiol may be provided in the form of magnolia bark extract.
- the magnolia bark extract can be extracted from the Magnolia plant belonging to the China pharmacopoeia. Further, the magnolia bark extract can include two pharmacologically active substances, magnolol and honokiol. Magnolol can be represented by the following chemical formula:
- honokiol can be represented by the following chemical formula:
- the honokiol and magnolol can work synergistically to help reduce visible inflammation by e.g. inhibiting protein complex NF-KB activation and activity through IKK (1KB kinase) enzyme inactivation. They can also inhibit the production of inducible nitric oxide synthase (iNOS), interleukin 8 (IL-8), tumor necrosis factor a (TNF- a), and/or cyclooxygenase-2 (COX-2).
- the magnolia bark extract can be included in the formulation in a liposomal form, e.g., with Lecithin as a carrier, which can advantageously allow the magnolia bark extract to dissolve within the lipids of the skin.
- magnolia bark extract can be provided as part of a larger magnolia mixture that includes magnolia bark extract, maltodextrin, lecithin, water, tocopherol, and grape seed extract for e.g. delivery and/or preservation.
- compositions described herein may contain at least one molecule of Formula I.
- the molecule of Formula I is ergothioneine (EGT).
- EGT ergothioneine
- the EGT can advantageously act as an antioxidant to scavenge free radicals and prolong cell activity and youthfulness of skin.
- the EGT can also advantageously recycle Vitamin C, which is an antioxidant that can reduce the extent of scarring and/or wrinkles of the skin.
- compositions described herein may contain ectoin.
- ectoin can be extracted from a halophilic bacteria called Halomonus Elongata, wherein ectoin compensates osmotic pressure in bacteria and stabilizes biopolymers to protect the bacteria against dehydration, high temperature, and UV-damage.
- the ectoin can be represented by the following formula:
- the ectoin can advantageously protect the skin from high temperatures, chemicals, surfactants, allergens, UV radiation, and dehydration.
- the ectoin can further act as a natural immune protector and support the skin's natural physiology.
- magnolia bark extract, ergothioneine, and ectoin can advantageously work synergistically via molecular markers to send messages to skin cells to help reduce visible inflammation, increase hydration, and support cell DNA, all key functions of maintaining healthy, youthful skin. All three ingredients can target the same molecular markers (hydration) and contribute to anti-inflammatory effects and fight free radicals, helping to prevent the breakdown of cell function and protecting against environmental and lifestyle stress factors.
- the compositions can include 10-30%w/w, such as 15-25%w/w, such as approximately 20% w/w ectoin; 40-80% w/w, such as 50-70%) w/w, such as 55-65%) w/w, such as approximately 60% w/w EGT; and 10-30%) w/w, such as 15-25%) w/w, such as approximately 20% w/w magnolia bark extract based on the total weight of the composition.
- the skincare formulation can be used as part of one or more skincare products, such as creams or pads.
- the skincare formulation can be used as part of a peel pad, a face and eye serum, a moisturizing cream with or without SPF 20, and/or an eye lift cream.
- the peel pad product shown in Figure 2 can include various acids such as azelaic, lactic and salicylic acid (e.g., in the form of willow bark extract) that exfoliate, smooth the skin and help stimulate collagen, and the formulation of magnolia bark extract, ectoin, and ergothioneine.
- the face and eye serum product shown in Figure 3 can include Vitamin C, and/or one or more of four different peptides which can achieve at least one of the following: help smooth and fill wrinkles, tighten the skin, reduce dark circles and puffiness, and even out skin tone.
- the four different peptides can be selected from the peptides described herein.
- the moisturizing cream of Figure 4 can include phospholipids, hyaluronic filling spheres, and an advanced moisture complex to achieve at least one of: hydrate, moisturize and help fill visible lines and wrinkles.
- the moisturizing cream of Figure 5 can include a peptide described herein, Vitamin C, and micronized zinc oxide to help stimulate collagen and elastin, brighten skin tone and provide UVA/UVB protection with a non-chalky appearance.
- the moisturizing cream of Figure 6 can include teprenone, Vitamin C, and micronized zinc oxide to help repair skin cell DNA, stimulate collagen and elastin and provide UVA/UVB protection with a non-chalky appearance.
- the eye lift cream of Figure 7 can include pinanediol, microalgae, Vitamin C, and caffeine to help achieve at least one of: help reduce the appearance of dark circles, firm and lift, brighten and improve circulation around the eye area.
- the skincare formulation and products can be used as part of a regimen to help reduce the visible signs of aging.
- the user can do at least one of the following: cleanse the skin to remove makeup, dirt, and oil; exfoliate the skin to remove the superficial layer of dead skin cells on the surface and promote the skin's natural ability to produce new collagen.
- a product including the skincare formulation described herein can be used to exfoliate, e.g., the peel pad described with respect to Figure 2, such as a peel pad made from 100%) cotton, cotton blends comprising about 10%>, about 20%>, about 30%>, about 40%>, about 50%), about 60%>, about 70%>, about 80%>, or about 90%> cotton, or synthetic materials.
- the user can treat the skin by depositing potent antioxidants, peptides, and collagen-stimulators into the skin.
- Such treatment can be performed, for example, with a face and eye serum such as the serum described with respect to Figure 3.
- the pores will be open so that the ingredients (such as the magnolia bark extract, ectoin, ergothioneine, Vitamin C and/or one or more peptides described herein) can easily penetrate the skin.
- the user can moisturize and protect the skin.
- the moisturizing creams of Figures 4, 5, or 6 can be used.
- the eye lift cream of Figure 7 can be used as desired to help firm and support circulation and reduce puffy eyes.
- composition comprising: at least one neolignan, at least one molecule of Formula I and ectoin, in an amount sufficient to result in a reduction of at least one symptom of skin aging when said composition is provided to a skin cell in a predetermined amount for a predetermined period of time.
- the molecule of Formula I is ergothioneine (EGT).
- the at least one neolignan is honokiol or a derivative thereof. Honokiol may be provided in the form of magnolia bark extract.
- the reduction of least one symptom of skin aging may be an improvement in the appearance of skin hyperpigmentation, a reduction in the appearance of crow's feet, an improvement in the elasticity of the skin, an improvement in the firmness or texture of the skin, and/or a reduction in the appearance of redness of the skin.
- the predetermined period of time is from about one day to about 24 weeks, or about 6 weeks, or at least about 4 weeks.
- a composition provided herein may also comprise at least one ultraviolet spectrum attenuating agent in an amount sufficient to reduce the exposure of said skin cell from ultraviolet radiation as compared to an otherwise identical composition not comprising said ultraviolet spectrum attenuating agent.
- the at least one ultraviolet spectrum attenuating agent comprises a plurality of nanoparticles.
- a nanoparticle as defined herein may include a microscopic particle of matter that is measured on the nanoscale, e.g. one that measures less than 1000 nanometers, less than 500 nanometers or less than 100 nanometers.
- the nanoparticles measure from about 1 to about 50 nanometers.
- the nanoparticles measure from about 0.5 to about 50 nanometers in diameter.
- the nanoparticles measure from about 1 to about 80 nanometers in diameter.
- the nanoparticles measure from about 10 to about 100 nanometers.
- 5% by weight of the ultraviolet spectrum attenuating agent is present as nanoparticles based on the total weight of the ultraviolet spectrum attenuating agent. In some cases up to 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%o, 90%), 95%) or 100% by weight of the ultraviolet spectrum attenuating agent is present as nanoparticles based on the total weight of the ultraviolet spectrum attenuating agent.
- the at least one ultraviolet spectrum attenuating agent comprises a plurality of microparticles.
- a microparticle as defined herein may include a particle of matter that is measured on the microscale, e.g. one that measures from about 0.1 to about 1000 micrometers.
- the microparticles measure less than 500 micrometers, less than 400 micrometers, less than 300 micrometers, less than 200 micrometers, less than 100 micrometers or less than 50 micrometers.
- the microparticles measure from about 1 to about 50 nanometers.
- the microparticles measure from about 0.1 to about 100 micrometers in diameter. In some cases, the microparticles measure from about 1 to about 100 micrometers in diameter.
- the microparticles measure from about 10 to about 100 micrometers. In some cases 5% by weight of the ultraviolet spectrum attenuating agent is present as microparticles based on the total weight of the ultraviolet spectrum attenuating agent. In some cases up to 10%>, 20%>, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% by weight of the ultraviolet spectrum attenuating agent is present as microparticles based on the total weight of the ultraviolet spectrum attenuating agent
- the at least one ultraviolet spectrum attenuating agent may comprise zinc oxide, titanium dioxide, derivatives or combinations thereof.
- a composition provided herein may also comprise zinc oxide and titanium dioxide.
- a composition provided herein comprises from about l%w/w to about 20%) w/w zinc oxide and from about 05 % w/w to about 20%> w/w titanium dioxide, based on the total weight of the composition.
- a composition provided herein comprises about 6% w/w zinc oxide and about 4.5% w/w titanium dioxide, based on the total weight of the composition.
- a composition provided herein may further comprise at least one polypeptide, derivative or fragment thereof, or protein, derivative or fragment thereof.
- the at least one polypeptide may be a neuropeptide.
- the neuropeptide is a pentapeptide that binds to an enkephelin receptor.
- the polypeptide comprises the sequence: Tyr-D-Ala-Gly-Phe-Leu.
- the neuropeptide is a synaptosomal associated protein- 25 (SNAP-25) or a fragment or variant thereof.
- the fragment of SNAP -25 may comprise a hexapeptide.
- the hexapeptide has a sequence comprising Glu-Glu-Met-Gln-Arg- Arg. In select cases the hexapeptide is Ac- Glu-Glu-Met-Gln-Arg-Arg -CONH 2 .
- a composition provided herein may further comprise at least one polypeptide, protein, or derivative or fragment thereof, wherein the at least one polypeptide is conjugated to a fatty acid.
- the fatty acid may be a saturated fatty acid.
- the saturated fatty acid is selected from propionic acid, butyric acid, valeric acid, caproic acid, enanthic acid, caprylic acid, pelargonic acid, capric acid, undecylic acid, lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, nonadecylic acid and arachidic acid.
- the composition may comprise a palmitic acid conjugate of a polypeptide comprising the sequence Gly-Gln-Pro-Arg (Pal-Gly-Gln-Pro-Arg).
- composition provided herein may further comprise at least one polypeptide, protein, or derivative or fragment thereof, wherein the at least one polypeptide comprises the sequence beta-Ala-His-Ser-His, or derivative thereof. In some cases, the at least one polypeptide comprises Ac-beta-Ala-His-Ser-His-OH.
- compositions described herein further comprising: a first polypeptide comprising the sequence Tyr-D-Ala-Gly-Phe-Leu (Pentapeptide- 18) or a derivative thereof; a second polypeptide comprising the sequence Ac- Glu-Glu-Met-Gln-Arg-Arg -CONH 2 (Acetyl Hexapeptide-8) or a derivative thereof; a third polypeptide comprising a palmitic acid conjugate of a polypeptide comprising the sequence Gly-Gln-Pro-Arg (Palmitoyl Tetrapeptide-7) or a derivative thereof; and a fourth polypeptide comprising the sequence Ac-beta-Ala-His-Ser- His (Acetyl Tetrapeptide-5) or a derivative thereof.
- compositions described herein comprising about 0.01%) w/w-25%) w/w neolignan, 0.1 % w/w-70% w/w molecule of Formula I, and 0.1 w/w-25%> w/w ectoin, based on the total weight of the composition.
- composition for cosmetic use comprising: at least one neolignan; at least one molecule of Formula I; and at least one neuropeptide.
- the molecule of Formula I is ergothioneine.
- the at least one neolignan is honokiol.
- the neuropeptide comprises the sequence: Tyr-D-Ala-Gly-Phe-Leu, or the sequence Glu-Glu-Met-Gln-Arg-Arg.
- composition for cosmetic use comprising ergothioneine; honokiol; ectoin; a first polypeptide comprising the sequence Tyr-D-Ala-Gly- Phe-Leu (Pentapeptide-18) or a derivative thereof; a second polypeptide comprising the sequence Ac- Glu-Glu-Met-Gln-Arg-Arg -CONH 2 (Acetyl Hexapeptide-8) or a derivative thereof; a third polypeptide comprising Pal-Gly-Gln-Pro-Arg (Palmitoyl Tetrapeptide-7) or a derivative thereof; and a fourth polypeptide comprising the sequence Ac-beta- Ala-His-Ser-His (Acetyl Tetrapeptide-5) or a derivative thereof.
- [0054] in some cases is a method of reducing the depth of wrinkles on the skin of a subject, comprising providing to the subject a composition for cosmetic use described herein in an amount and time sufficient for reducing the depth of wrinkles on the skin of said subject.
- composition for cosmetic use described herein in an amount and time sufficient for brightening the skin tone of said subject.
- compositions for cosmetic use comprising: at least one neolignan; at least one molecule of Formula I; and at least one ultraviolet spectrum attenuating agent comprising a plurality of nanoparticles or microparticles.
- the molecule of Formula I is ergothioneine.
- the neolignan may be honokiol.
- the at least one ultraviolet spectrum attenuating agent comprises zinc oxide, titanium dioxide, derivatives or combinations thereof.
- the composition may also comprise a plurality of hyaluronic microspheres.
- composition for cosmetic use comprising ergothioneine; honokiol; ectoin; zinc oxide; titanium dioxide; hyaluronic acid or a salt thereof.
- the composition comprises sodium hyaluronate.
- a method of reducing the appearance of fine lines on the skin of a subject comprising providing to said subject a composition for cosmetic use described herein, in an amount and time sufficient for reducing the appearance of fine lines on the skin of said subject.
- the subject maybe a human. In some cases, the subject maybe a human in need of the methods described herein.
- the honokiol is provided in the form of magnolia bark extract.
- the magnolia bark extract may be in liposomal form.
- compositions described herein comprise about 0.01% w/w-25% w/w magnolia bark extract, 0.1% w/w-70% w/w ergothioneine, and 0.1 w/w-25% w/w ectoin, based on the total weight of the composition.
- Composition described herein may be in the form of at least one of a cream, lotion, serum, gel and moisturizer.
- Compositions described herein may further comprise at least one of Vitamin C Ester, Peptide Blends, Alpha Hydroxy and Beta Hydroxy Acids, Mushroom Ferment Extract, Multi-mineral Blends, Phospholipids, Caffeine, and Micro-Algae Blends.
- composition comprising cyclopentasiloxane, CI 2- 15 Alkyl Benzoate, Titanium Dioxide, Zinc Oxide, Dimethicone, Polyglyceryl-3 Polydimethylsiloxyethyl
- Dimethicone, Dimethicone/PEG-10/15 Crosspolymer Stearic Acid, Aluminum Hydroxide, Sodium Chloride, Glycerin, Magnolia Officinalis Bark Extract, Ectoin, Caprylyl Glycol, Teprenone, Sodium Hyaluronate, Vitis Vinifera (Grape) Seed Extract, Tetrahexyldecyl
- Phenoxyethanol Ethylhexylglycerin, Butylene Glycol, Hexylene Glycol, Fragrance, Mica and Silica.
- compositions wherein said composition comprises Potassium Azeloyl Diglycinate, Hamamelis Virginiana (Witch Hazel) Extract, Glycerin, Methyl Gluceth- 20, Magnolia Officinalis Bark Extract, Ergothioneine, Ectoin, Pentylene Glycol, Salix Nigra (Willow) Bark Extract, Magnesium Aspartate, Zinc Gluconate, Copper Gluconate, Microcitrus Austraiasica Fruit Extract, Mucor Miehei Extract, Glucosamine HC1, Urea, Phenoxyethanol, Ethylhexylglycerin, Polysorbate 20, Magnolia Glauca Flower Water, Sodium PCA, Potassium Sorbate, Allantoin, Dipotassium Glycyrrhizate, Alcohol Denatured, Disodium EDTA, Lactic Acid, Maltodextrin, Lecithin, Tocopherol, Vitis Vinifera (Grape) Seed Extract
- Damascena Flower Oil Pelargonium Graveolens Oil, Citrus Medica Limonum (Lemon) Peel Oil, Camellia Sinensis Leaf (Green Tea) Extract, Mentha Viridis (Spearmint) Leaf Oil, and Juniperus Virginiana Oil.
- compositions wherein said composition comprises Glycerin, Ricinus Communis (Castor) Seed Oil, Cetearyl Olivate, Lecithin, Caprylic/Capric Triglyceride, Sorbitan Olivate, Cetearyl Alcohol, Dimethicone, Ergothioneine, Isosorbide Dicaprylate, Glyceryl Behenate, Ethyl Linoleate, Ethylhexyl Palmitate, Silica Dimethyl Silylate, Butylene Glycol, Sodium Hyaluronate, Magnolia Officinalis Bark Extract, Ectoin, Tetrahexyldecyl Ascorbate, Panthenol, Hydrogenated Castor Oil, Cera Alba, Copernicia Cerifera (Carnauba) Wax, Sodium PCA, Urea, Trehalose, Triacetin, Polyquatemium-51 , Methylglucoside Phosphate, Copper Lysinate/Prolinate, Cet
- composition wherein said composition comprises
- the peel pad comprises a composition described herein adsorbed or absorbed upon it.
- the facial pad wherein said pad comprises Potassium Azeloyl Diglycinate, Hamamelis Virginiana (Witch Hazel) Extract, Glycerin, Methyl Gluceth-20, Magnolia Officinalis Bark Extract, Ergothioneine, Ectoin, Pentylene Glycol, Salix Nigra (Willow) Bark Extract, Magnesium Aspartate, Zinc Gluconate, Copper Gluconate, Microcitrus Austraiasica Fruit Extract, Mucor Miehei Extract, Glucosamine HC1, Urea,
- a method of reducing the visible signs of skin aging including: exfoliating the skin with a composition described herein; treating the skin with a composition described herein; and/or moisturizing the skin with a composition described herein.
- the exfoliating, treating and/or moisturizing may be repeated two, three, four, or five times daily.
- the exfoliating, treating and/or moisturizing may be repeated two, three, four, or five times on alternate days.
- the exfoliating, treating and/or moisturizing may be repeated for about 10, about 15, about 20, about 25, about 30, about 45, about 50, about 60, about 70, about 75, or about 90 days.
- composition described herein wherein the composition is an antioxidant composition.
- the composition comprises at least two ingredients which provide synergistic antioxidant effect.
- the synergistic antioxidant effect is studied by exposing HaCaT cells to said composition, followed by exposing said cells to TBHP.
- compositions comprising combining: at least one neolignan; ectoin; and a molecule of Formula I.
- the molecule of Formula I In some cases, the molecule of
- Formula I is EGT.
- the method further comprising at least one ingredient selected from the group consisting of: Potassium Azeloyl Diglycinate, Hamamelis Virginiana (Witch Hazel) Extract, Glycerin, Methyl Gluceth-20, Magnolia Officinalis Bark Extract, Pentylene Glycol, Salix Nigra (Willow) Bark Extract, Magnesium Aspartate, Zinc Gluconate, Copper Gluconate, Microcitrus Austraiasica Fruit Extract, Mucor Miehei Extract, Glucosamine HC1, Urea, Phenoxyethanol, Ethylhexylglycerin, Polysorbate 20, Magnolia Glauca Flower Water, Sodium PCA, Potassium Sorbate, Allantoin, Dipotassium Glycyrrhizate, Alcohol Denatured, Disodium EDTA, Lactic Acid, Maltodextrin, Lecithin, Tocopherol, Vitis Vinifera (Grape) Seed Extract,
- Officinalis Bark Extract Ergothioneine, Ectoin, Palmitoyl Tetrapeptide-7, Acetyl Tetrapeptide-5, Tetrahexyldecyl Ascorbate, Tyrosine, Hesperidin Methyl Chalcone, Tricholoma Matsutake Extract, Corallina Officinalis Extract, Sodium Hyaluronate, Sodium Potassium Aluminum Silicate, Silica, Pullulan, Steareth-20, Dipeptide-2, Ethylcellulose, Polysorbate 20,
- the composition is in the form of at least one selected from the group consisting of a cream, lotion, serum, gel and moisturizer.
- kits comprising a composition described herein, and at least one container.
- a kit may further comprise instructions for use.
- a system comprising at least two kits described herein. In some cases, at least two of the at least two kits are different
- Example 1 Clinical Evaluation of compositions provided herein:
- Benefits of the compositions described herein are evaluated in a controlled, independent single-blind study using advanced imaging technology, overseen by a dermatologist.
- the goal is to evaluate at least one of the top 10 visible signs of aging— lines and wrinkles, loss of elasticity (firmness), spots and pigmentation, redness, loss of radiance, uneven skin texture (roughness), loss of moisture, sallowness (dull skin), dehydration, and thin skin.
- a six -week clinical efficacy trial is performed on the compositions provided herein with a third party testing facility using advanced imaging technology.
- the testing facility randomly recruits female subjects between 35 and 60 years who have no knowledge of the product details and who use the compositions described herein twice daily per our standard directions for use.
- STEP 1 Cleansing using a composition provided herein.
- STEP 2 Peel Pads comprising a composition provided herein.
- STEP 3 Serum comprising a composition provided herein.
- STEP 4 (AM) Moisturizer SPF 20 comprising a composition provided herein.
- STEP 4 (PM) Moisture Injection Cream comprising a composition provided herein.
- Analysis includes standard white light, cross-polarized and UV lighting to record and measure surface and subsurface skin conditions.
- UV photography provides the most complete data set available for sun damage assessment and analysis, including UV fluorescence imaging.
- a trained technician takes digital images of the face of each subject. Using ImagePro® software, the images are analyzed to determine changes in the depth of global facial wrinkles, skin radiance/luminosity and skin lightness.
- Cleansing Balm Ingredients included Sesamum Indicum (Sesame) Seed Oil, Oleic Acid, Oleth-20, Trihydroxystearin, Polyglyceryl-3 Diisostearate, Glyceryl Monostearate, Prunus Domestica Seed Oil, Cera Alba, Linoleic Acid, Silica, Water, Stearyl Glycyrrhetinate, Linolenic Acid, Ascorbyl Palmitate, Tetrahexyldecyl Ascorbate, Bisabolol, Tocotrienols, Tocopheryl Acetate, Stearic Acid, Glycerin, Tocopherol, Maltodextrin, Squalene, Beta-Glucan, Palmitic Acid, Phenoxyethanol, Dehydroacetic Acid, Benzoic Acid, Ethylhexylglycerin, and Fragrance.
- Sesamum Indicum Sesamum Indicum (Sesame) Seed Oil, Oleic Acid, Oleth-20, Trihydroxy
- Peel Pads Ingredients included Water, Potassium Azeloyl Diglycinate, Hamamelis Virginiana (Witch Hazel) Extract, Glycerin, Methyl Gluceth-20, Magnolia Officinalis Bark Extract, Ergothioneine, Ectoin, Pentylene Glycol, Salix Nigra (Willow) Bark Extract,
- Quattro-Peptide Face and Eye Serum Ingredients included Water, Pentapeptide-18, Acetyl Hexapeptide-8, Caprylyl Methicone, Glycerin, Butylene Glycol, Beta Glucan (Oat), Isosorbide Dicaprylate, Dimethicone, Isostearyl Alcohol, Butylene Glycol Cocoate,
- Polyacrylate-13 Magnolia Officinalis Bark Extract, Ergothioneine, Ectoin, Palmitoyl
- Tetrapeptide-7 Acetyl Tetrapeptide-5, Tetrahexyldecyl Ascorbate, Tyrosine, Hesperidin Methyl Chalcone, Tricholoma Matsutake Extract, Corallina Officinalis Extract, Sodium Hyaluronate, Sodium Potassium Aluminum Silicate, Silica, Pullulan, Steareth-20, Dipeptide-2, Ethylcellulose, Polysorbate 20, Polyisobutene, Dimethiconol, Panthenol, Oryza Sativa (Rice) Bran Oil, Lecithin, Allantoin, Xanthan Gum, Elaeis Guineensis Oil, Tocotrienols, Tocopherol, Phenoxyethanol, Maltodextrin, Vitis Vinifera (Grape) Seed Extract, Sodium Phytate, Fragrance,
- Moisturizer SPF 20 Ingredients included Titanium Dioxide 1%. Zinc Oxide 10%.
- Inactive Ingredients Water, Caprylic/Capric Triglyceride, Glyceryl Stearate, Ergothioneine, Cetyl Alcohol, Dimethicone, Phenyl Trimethicone, Glycerin, Ethylhexyl Palmitate, Magnolia Officinalis Bark Extract, Ectoin, Palmitoyl Hexapeptide-19, Tocopherol, Sodium Hyaluronate, Vitis Vinifera (Grape) Seed Extract, Sodium PCA, Lecithin, Jojoba Esters, Phytic Acid, Cetearyl Alcohol, Caprylyl Glycol, Hydrogenated Lecithin, Citric Acid, Tetrahexyldecyl Ascorbate, Polyacrylamide, Silica, Xanthan Gum, Ceteareth-20, C13-14 Isoparaffin, Glyceryl Isostearate, Polyhydroxystearic Acid, Glyceryl Polyacrylate, Maltodextrin, Hydroxyethyl Acrylate/Sodium Acryl
- Moisture Injection Cream Ingredients included Water, Glycerin, Ricinus Communis (Castor) Seed Oil, Cetearyl Olivate, Lecithin, Caprylic/Capric Triglyceride, Sorbitan Olivate, Cetearyl Alcohol, Dimethicone, Ergothioneine, Isosorbide Dicaprylate, Glyceryl Behenate, Ethyl Linoleate, Ethylhexyl Palmitate, Silica Dimethyl Silylate, Butylene Glycol, Sodium Hyaluronate, Magnolia Officinalis Bark Extract, Ectoin, Tetrahexyldecyl Ascorbate, Panthenol, Hydrogenated Castor Oil, Cera Alba, Copernicia Cerifera (Carnauba) Wax, Sodium PCA, Urea, Trehalose, Triacetin, Polyquaternium-51 , Methylglucoside Phosphate, Copper Lysinate/Prolinate,
- a six -week clinical efficacy trial was commissioned with a third party testing facility using advanced imaging technology.
- the testing facility randomly recruited 43 female subjects between 35 and 55 years who had no knowledge of the product details and who used the four steps outlined below, twice daily per our standard directions for use. Participants completed a "wash-out" period before starting the Regimen and refrained from using any other facial skincare treatments including retinoids, AHA products, exfoliating scrubs or Clarisonic devices other than the compositions used in this example.
- STEP 3 Quattro-Peptide Face and Eye Serum.
- STEP 4 Moisturizer SPF 20.
- the analysis included standard white light, cross-polarized and UV lighting to record and measure surface and subsurface skin conditions.
- UV photography provides the most complete data set available for sun damage assessment and analysis, including UV fluorescence imaging.
- a trained technician took digital images of the face of each subject.
- ImagePro® software the images were analyzed to determine changes in the depth of global facial wrinkles, skin radiance/luminosity and skin lightness.
- compositions described herein were evaluated in an extended study over 30 days.
- the goal was to evaluate one or more visible signs of aging, e.g. lines and wrinkles, loss of elasticity (firmness), spots and pigmentation, redness, loss of radiance, uneven skin texture (roughness), loss of moisture, sallowness (dull skin), dehydration, and thin skin.
- the study was performed in a control group of 17 women and 1 man, aged 35-55, with skin ranging from normal to dry, aging skin. Subjects used the compositions provided in Example 2.
- Test System Human Keratinocytes, e.g. spontaneously transformed aneuploid immortal keratinocyte cell line from adult human skin (HaCaT).
- 96-well plates of HaCaT cells are used for the study. At least one plate is pre-loaded with DCFDA for 30 minutes prior to treatment. The second plate, used to assess glutathione (GSH) depletion, is not pre-treated in any way. After DCFDA solution is removed, treatments with antioxidants begin. After 1 hour, antioxidant treatment media is removed. Generation of reactive oxygen species is induced by applying tert-butylhydroperoxide (TBHP) to the cells at a concentration of 1% (v/v).
- TBHP tert-butylhydroperoxide
- Samples are treated in three ways: Group A receives phosphate buffered saline (no TBHP), Group B receives 1% TBHP, and Group C is pretreated with compositions provided herein followed by treatment oxidant 1% TBHP.
- Historic data has shown that 1 hour is sufficient to elicit DCFDA fluorescence and GSH depletion; however cells treated with DCFDA can be read at 1, 3, 6 and 24 hours post-peroxide dose to assess oxidative stress. After exposure total glutathione and leakage of lactate dehydrogenase (LDH) (a general cytotoxicity marker) is assessed.
- LDH lactate dehydrogenase
- Compositions provided herein are tested individually and in combination. The antioxidant properties of the compositions are determined by comparing the response to the pro-oxidant in Group B to the response of the antioxidant plus pro-oxidant in group C.
- compositions provided herein have an antioxidant effect that is greater than the antioxidant effect of each ingredient taken separately. In some cases, the antioxidant effect of a composition provided herein is greater than the expected additive antioxidant effect of each of the ingredients.
- Example 5 Stability testing:
- a composition described herein containing at least one of neolignan, ectoin, and the molecule of Formula I is placed sideways in a 25°C ⁇ 2°C /60% Relative Humidity (RH) ⁇ 5% Relative Humidity (RH) environmental storage chamber for different intervals to yield a period of 6 months and in a 40°C ⁇ 2°C/75%RH ⁇ 5% RH environmental storage chamber for different intervals to yield a period of 6 months.
- RH Relative Humidity
- RH Relative Humidity
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2966778A CA2966778A1 (en) | 2014-11-03 | 2015-11-03 | Skincare formulations and regimens |
AU2015343218A AU2015343218A1 (en) | 2014-11-03 | 2015-11-03 | Skincare formulations and regimens |
JP2017543289A JP2018501298A (en) | 2014-11-03 | 2015-11-03 | Skin care formulations and regimens |
EP15857708.0A EP3215495A4 (en) | 2014-11-03 | 2015-11-03 | Skincare formulations and regimens |
BR112017009342-1A BR112017009342A2 (en) | 2014-11-03 | 2015-11-03 | Skin Care Formulations & Treatments |
CN201580072204.9A CN107108544A (en) | 2014-11-03 | 2015-11-03 | Skin care formulation and scheme |
KR1020177014834A KR20170083068A (en) | 2014-11-03 | 2015-11-03 | Skincare formulations and regimens |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462074536P | 2014-11-03 | 2014-11-03 | |
US62/074,536 | 2014-11-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016073529A1 true WO2016073529A1 (en) | 2016-05-12 |
Family
ID=55851438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/058897 WO2016073529A1 (en) | 2014-11-03 | 2015-11-03 | Skincare formulations and regimens |
Country Status (9)
Country | Link |
---|---|
US (2) | US10045925B2 (en) |
EP (1) | EP3215495A4 (en) |
JP (1) | JP2018501298A (en) |
KR (1) | KR20170083068A (en) |
CN (1) | CN107108544A (en) |
AU (1) | AU2015343218A1 (en) |
BR (1) | BR112017009342A2 (en) |
CA (1) | CA2966778A1 (en) |
WO (1) | WO2016073529A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170137004A (en) * | 2016-06-02 | 2017-12-12 | 마리 케이 인코포레이티드 | Cosmetic compositions |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200030214A1 (en) * | 2017-03-06 | 2020-01-30 | Merck Patent Gmbh | Use of compatible solutes |
US11504355B2 (en) | 2018-03-05 | 2022-11-22 | Mironova Innovations, Llc | Ergothioneine compositions and methods for maintaining and/or increasing vitamin C levels in cells and organisms |
EP3873480A4 (en) * | 2018-10-30 | 2022-10-19 | Advance Nanotek Ltd. | Anti-acne composition |
CN109276578A (en) * | 2018-11-07 | 2019-01-29 | 上海上水和肌化妆品有限公司 | The composition and preparation method thereof for promoting the anti-saccharification of skin is converted by energy |
JP2020150822A (en) * | 2019-03-19 | 2020-09-24 | 三菱ケミカルフーズ株式会社 | Oils and fats, method for producing oils and fats, and oxidation inhibitor for oils and fats |
CN110327242B (en) * | 2019-07-29 | 2021-07-23 | 华熙生物科技股份有限公司 | Method for inhibiting ergothioneine photodegradation and application thereof |
CN110478264A (en) * | 2019-09-29 | 2019-11-22 | 上海克琴科技有限公司 | A kind of cosmetic or skin composition with delay skin aging effect |
WO2021237214A1 (en) * | 2020-05-22 | 2021-11-25 | Ilera Derm LLC | Compositions for treating acne and dermatological conditions |
AU2021276680A1 (en) | 2020-05-22 | 2023-01-19 | Ilera Derm LLC | Compositions for treating acne and dermatological conditions |
CN111743800A (en) * | 2020-07-10 | 2020-10-09 | 杭州科腾生物制品有限公司 | Composition and preparation method and application thereof |
CN111991293B (en) * | 2020-09-13 | 2021-04-16 | 广州丽彦妆生物科技有限公司 | Skin care essence lotion for treating and repairing sensitive acne skin and preparation method thereof |
KR102309300B1 (en) * | 2020-09-18 | 2021-10-07 | 주식회사 아쉬세븐 | Functional cosmetic composition for skin wrinkle improvement |
CN113440426B (en) * | 2021-07-01 | 2023-03-21 | 上海应用技术大学 | Honokiol double inclusion and preparation method and application thereof |
CN113648236A (en) * | 2021-08-26 | 2021-11-16 | 上海拜思丽实业有限公司 | Antioxidant composition, antioxidant cosmetic composition and preparation method thereof |
CN114224779A (en) * | 2021-12-27 | 2022-03-25 | 广州睿森生物科技有限公司 | Eye repair composition and application thereof |
CN114085266B (en) * | 2022-01-07 | 2022-05-10 | 浙江湃肽生物有限公司深圳分公司 | Peptide conjugate derivative based on palmitoyl tetrapeptide-7, preparation method and application |
WO2023196200A1 (en) | 2022-04-08 | 2023-10-12 | Colgate-Palmolive Company | Skin care compositions comprising vitamin e and vitamin b3 |
CN114569491B (en) * | 2022-04-18 | 2023-08-18 | 华熙生物科技股份有限公司 | Composition for inhibiting grease generation and application thereof |
CN115517999B (en) * | 2022-10-26 | 2023-09-15 | 广州艾卓生物科技股份有限公司 | Anti-aging composition and application thereof in beauty and skin care |
CN115998661A (en) * | 2023-01-18 | 2023-04-25 | 华熙生物科技股份有限公司 | Sensitive muscle repair composition and application thereof |
CN116196234A (en) * | 2023-03-09 | 2023-06-02 | 江苏仅三生物科技有限公司 | Skin care composition with whitening effect of brightening Yan Diliang and application |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050096256A1 (en) * | 2003-07-01 | 2005-05-05 | President And Fellows Of Harvard College | Compositions for manipulating the lifespan and stress response of cells and organisms |
FR2865398A1 (en) * | 2004-01-23 | 2005-07-29 | Jean Noel Thorel | Cosmetic or dermatological composition containing specific amino acids and mannitol or its derivative, useful for protecting e.g. skin and hair against ultraviolet light |
US20070065396A1 (en) * | 2005-09-21 | 2007-03-22 | Tracie Martyn International, Llc | Topical macqui berry formulation |
US20090042846A1 (en) * | 2005-08-19 | 2009-02-12 | Bioderm Research | Topical Delivery System for Phytosterols |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006050650A1 (en) * | 2006-10-24 | 2008-04-30 | Henkel Kgaa | Hair treatment agent, useful to e.g. increase the elasticity of keratinic fibers, comprises a copolymer of first monomer and second monomer comprising e.g. acrylic acid, a silicone and a caring agent comprising e.g. vitamins and ubiquinone |
KR101527829B1 (en) * | 2007-04-19 | 2015-06-12 | 마리 케이 인코포레이티드 | Magnolia extract containing compositions |
FR2939669B1 (en) * | 2008-12-17 | 2011-03-25 | Oreal | COSMETIC METHOD FOR CONTROLLING SKIN BLIND INDUCED BY UV RADIATION; Compositions. |
DE102009045998A1 (en) * | 2009-10-26 | 2011-04-28 | Henkel Ag & Co. Kgaa | Sunscreen compositions |
ES2349972B1 (en) * | 2009-02-16 | 2011-11-24 | Lipotec, S.A. | USEFUL PEPTIDES IN THE TREATMENT AND / OR CARE OF SKIN, MUCOUSES AND / OR LEATHER LEATHER AND ITS USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS. |
AU2014233420A1 (en) * | 2013-03-15 | 2015-11-12 | Laboratory Skin Care, Inc. | Fine dry particulate retinoid active agent compositions and topical formulations including the same |
-
2015
- 2015-11-03 BR BR112017009342-1A patent/BR112017009342A2/en not_active Application Discontinuation
- 2015-11-03 CN CN201580072204.9A patent/CN107108544A/en active Pending
- 2015-11-03 CA CA2966778A patent/CA2966778A1/en not_active Abandoned
- 2015-11-03 US US14/931,744 patent/US10045925B2/en active Active
- 2015-11-03 JP JP2017543289A patent/JP2018501298A/en active Pending
- 2015-11-03 AU AU2015343218A patent/AU2015343218A1/en not_active Abandoned
- 2015-11-03 KR KR1020177014834A patent/KR20170083068A/en unknown
- 2015-11-03 EP EP15857708.0A patent/EP3215495A4/en not_active Withdrawn
- 2015-11-03 WO PCT/US2015/058897 patent/WO2016073529A1/en active Application Filing
-
2019
- 2019-02-22 US US16/283,228 patent/US20200022893A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050096256A1 (en) * | 2003-07-01 | 2005-05-05 | President And Fellows Of Harvard College | Compositions for manipulating the lifespan and stress response of cells and organisms |
FR2865398A1 (en) * | 2004-01-23 | 2005-07-29 | Jean Noel Thorel | Cosmetic or dermatological composition containing specific amino acids and mannitol or its derivative, useful for protecting e.g. skin and hair against ultraviolet light |
US20090042846A1 (en) * | 2005-08-19 | 2009-02-12 | Bioderm Research | Topical Delivery System for Phytosterols |
US20070065396A1 (en) * | 2005-09-21 | 2007-03-22 | Tracie Martyn International, Llc | Topical macqui berry formulation |
Non-Patent Citations (2)
Title |
---|
KANG ET AL.: "Wnt/B-Catenin Signaling Mediates the Antitumor Activity of Magnolol in Colorectal Cancer Cells", MOLECULAR PHARMACOLOGY, vol. 82, no. 2, 1 May 2012 (2012-05-01), pages 168 - 177, XP055218824, DOI: doi:10.1124/mol.112.078535 * |
See also references of EP3215495A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170137004A (en) * | 2016-06-02 | 2017-12-12 | 마리 케이 인코포레이티드 | Cosmetic compositions |
KR102402791B1 (en) | 2016-06-02 | 2022-05-26 | 마리 케이 인코포레이티드 | Cosmetic compositions |
Also Published As
Publication number | Publication date |
---|---|
US20200022893A1 (en) | 2020-01-23 |
KR20170083068A (en) | 2017-07-17 |
BR112017009342A2 (en) | 2018-07-03 |
AU2015343218A1 (en) | 2017-05-25 |
EP3215495A1 (en) | 2017-09-13 |
CA2966778A1 (en) | 2016-05-12 |
EP3215495A4 (en) | 2018-05-02 |
US10045925B2 (en) | 2018-08-14 |
US20160120781A1 (en) | 2016-05-05 |
CN107108544A (en) | 2017-08-29 |
JP2018501298A (en) | 2018-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200022893A1 (en) | Skincare Formulations and Regimens | |
US11433020B2 (en) | Brightening skin care serums | |
EP3206686B1 (en) | Gamma-diketones for treatment and prevention of aging skin and wrinkles | |
ES2659453T3 (en) | Topical compositions comprising Pichia anomala and chicory root extracts | |
KR101772139B1 (en) | Skin care formulations | |
KR102267689B1 (en) | Cosmetic compositions and uses thereof | |
CA2839453C (en) | Composition comprising a moisturizing agent, a desquamation agent, a mattifying agent, and an agent that increases skin luminosity | |
KR20180051647A (en) | Topical skin care formulations comprising plant extracts | |
MX2008009252A (en) | Compositions comprising kakadu plum extract or acai berry extract. | |
AU2011227198A1 (en) | Topical skin care composition | |
WO2008139182A2 (en) | Skin care composition | |
KR102083294B1 (en) | A composition for skin reproduction containing extracts of abeliophyllum distichum and extract thereof having skin reproduction effect | |
JP2008518042A (en) | A composition comprising a rosemary (Rosmarinusofficinalis) plant extract, an Alpinia plant extract, and a DNA repair enzyme. | |
ES2616928T3 (en) | Cosmetic composition comprising banana, lotus and clover serum fractions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15857708 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2966778 Country of ref document: CA Ref document number: 2017543289 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2015343218 Country of ref document: AU Date of ref document: 20151103 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20177014834 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015857708 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017009342 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112017009342 Country of ref document: BR Kind code of ref document: A2 Effective date: 20170503 |